H.C. Wainwright lowered the firm’s price target on Kezar Life Sciences to $7 from $20 and keeps a Buy rating on the shares. The firm reduced estimates to reflect the company’s near-term outlook and changing market dynamics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks